BioCentury
ARTICLE | Company News

Ganymed, Astellas deal

November 2, 2016 5:54 PM UTC

Astellas will acquire cancer company Ganymed for €422 million ($459.4 million) in cash. Ganymed shareholders are also eligible for up to €860 million ($936.2 million) in undisclosed milestones tied to...

BCIQ Target Profiles

CLND18.2